Shots:
- The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in non-hospitalized adult patients with COVID-19 with 1 risk factor associated with poor disease outcomes & symptom onset within 5 days before randomization
- At the interim analysis, the therapy showed a ~50% reduction in risk of hospitalization or death; patients were hospitalized or died (7.3% vs 14.1%) @ 29Day following randomization & no deaths were reported
- The companies continue to discuss additional measures and collaborations to accelerate global access to molnupiravir. The therapy is also being evaluated in the P-III MOVe-AHEAD study as monothx. for post-exposure prophylaxis to prevent COVID-19 within households
Click here to read the full press release/ article | Ref: Merck | Image: Ridgeback
The post Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021 first appeared on PharmaShots.
